Dhanalakshmi Sivanandhan

This inventor holds 9 USPTO granted patents and 3 published patent applications and 5 EPO patents. Top assignees: Jubilant Biosys Limited, Jubilant Epicore LLC, Jubilant Episcribe LLC. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dhanalakshmi Sivanandhan. Retrieved from https://idiyas.com/inventor/dhanalakshmi-sivanandhan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 3)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 7.7

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Bengaluru, IN (2019 - 2022)
Yeshwanthpur Bangalore, IN (2022)

Company Filing History:

5 out of 5

Jubilant Biosys Limited

Jubilant Episcribe LLC

patent

4. 1 out of 834,570

Other

patents

Years Active: 2019-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12479797 - Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors (2025-11-25),

2. 11529341 - Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation (2022-12-20),

3. 11459338 - Heterocyclic compounds as PRMT5 inhibitors (2022-10-04),

4. 11352322 - Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors (2022-06-07),

5. 11319326 - Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer (2022-05-03),

6. 11267820 - Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors (2022-03-08),

7. 10689395 - Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors (2020-06-23),

8. 10689390 - Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer (2020-06-23),

9. 10273224 - Substituted pyrimidine compounds, compositions and medicinal applications thereof (2019-04-30),

Title: Dhanalakshmi Sivanandhan: Innovator in Pharmaceutical Compounds

Introduction

Dhanalakshmi Sivanandhan is a prominent inventor based in Bengaluru, India. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target critical biological interactions. With a total of 9 patents to her name, her work is paving the way for advancements in therapeutic agents.

Latest Patents

Among her latest patents, Dhanalakshmi has developed bicyclic compounds that act as inhibitors of the PD-1/PD-L1 interaction and activation. These compounds, described in her patent, include various forms such as polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts. Additionally, she has patented heterocyclic compounds that serve as PRMT5 inhibitors. These compounds are crucial for treating diseases related to cellular growth, including malignant tumors, schizophrenia, Alzheimer's disease, and Parkinson's disease.

Career Highlights

Dhanalakshmi has worked with notable companies in the pharmaceutical sector, including Jubilant Biosys Limited and Jubilant Episcribe LLC. Her experience in these organizations has allowed her to refine her skills and contribute to innovative research in drug development.

Collaborations

Dhanalakshmi has collaborated with esteemed colleagues such as Sridharan Rajagopal and Saravanan Vadivelu. These partnerships have enhanced her research capabilities and broadened the impact of her inventions.

Conclusion

Dhanalakshmi Sivanandhan is a trailblazer in the field of pharmaceutical innovations. Her patents and collaborative efforts are instrumental in advancing therapeutic solutions for various diseases. Her work continues to inspire future generations of inventors in the pharmaceutical industry.

Profile summary based on public USPTO records.